Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of

4 Likes

I found this in another page: Selectively targets the dopamine D2 receptor-dependent, indirect pathway associated with Parkinson’s disease and is intended to generate the positive effects of L-dopa and deep brain stimulation, the current standard of care for Parkinson’s disease, without the adverse effects

1 Like